The storied but out-of-favor name could retrace a recent rally, which could present an opportunity to buy.
Also, electric vehicle maker Nio Inc. already has triggered an entry point.
That's when time is up and their obligations to buy or sell shares either disappear or end with exercises at the option's in-the-money value.
Ocular Therapeutix and TG Therapeutics are still promising companies, but their recent runs higher make them pricey at this point.
Three of the four restaurant operators are worth at least a nibble, but one doesn't look appetizing right now.
They leave investors in a precarious position, as there is not a lot of a value left in what has become a very picked-over market.
The technical signs for the e-commerce platform and visual discovery platform appear favorable.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
DocuSign, Lululemon Athletica, Splunk and Walmart are the diverse quartet of stocks that we're tracking.
One of the three stocks looks OK to ease into now, but the technical signals indicate it would be best to wait on the other two.